Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Clin Croat ; 62(Suppl2): 104-109, 2023 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38966028

RESUMO

New minimally invasive procedures to treat benign prostatic hyperplasia (BPH) have been developed in the last 20 years. With the introduction of laser enucleation techniques in prostate surgery, previous standard surgical procedures (open retropubic or transvesical adenectomy and transurethral resection of the prostate) have become less relevant, especially in case of very large prostates. The objective of this paper is to describe the experience and results of thulium:YAG laser application in BPH treatment in our department. In the last five years, 246 patients underwent thulium:YAG laser enucleation of the prostate (ThuLEP) due to BPH or lower urinary tract symptoms following complete urologic evaluation. The mean age of our patients was 73 (range 51-95) years and mean duration of surgery was 92 minutes. The mean weight of enucleated tissue was 73 grams. A low rate of intraoperative and early postoperative complications and short length of stay proved minimal invasiveness of this procedure, which results in significant improvements in urodynamic parameters and substantially reduces the post-void residual urine volume. The most important surgical and technical characteristics (enucleation and low-power laser application) make ThuLEP a safe and efficient surgical method not limited by the prostate volume. ThuLEP has a potential to displace the current standard surgical procedures to treat BPH.


Assuntos
Terapia a Laser , Lasers de Estado Sólido , Hiperplasia Prostática , Túlio , Humanos , Masculino , Hiperplasia Prostática/cirurgia , Idoso , Pessoa de Meia-Idade , Lasers de Estado Sólido/uso terapêutico , Idoso de 80 Anos ou mais , Terapia a Laser/métodos , Prostatectomia/métodos
2.
APMIS ; 124(4): 252-6, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26765960

RESUMO

Human gastric diseases have shown significant changes in the activity and expression of superoxide dismutase (SOD) isoforms. The aim of this study was to detect Mn-SOD activity and expression in the tissue of gastric mucosa, primarily in chronic gastritis (immunohistochemical Helicobacter pylori-negative gastritis, without other pathohistological changes) and to evaluate their possible connection with pathohistological diagnosis. We examined 51 consecutive outpatients undergoing endoscopy for upper gastrointestinal symptoms. Patients were classified based on their histopathological examinations and divided into three groups: 51 patients (archive samples between 2004-2009) with chronic immunohistochemical Helicobacter pylori-negative gastritis (mononuclear cells infiltration were graded as absent, moderate, severe) divided into three groups. Severity of gastritis was graded according to the updated Sydney system. Gastric tissue samples were used to determine the expression of Mn-SOD with anti-Mn-SOD Ab immunohistochemically. The Mn-SOD expression was more frequently present in specimens with severe and moderate inflammation of gastric mucosa than in those with normal mucosa. In patients with normal histological finding, positive immunoreactivity of Mn-SOD was not found. Our results determine the changes in Mn-SOD expression occurring in the normal gastric mucosa that had undergone changes in the intensity of chronic inflammatory infiltrates in the lamina propria.


Assuntos
Mucosa Gástrica/enzimologia , Gastrite/diagnóstico , Gastrite/enzimologia , Superóxido Dismutase/genética , Anticorpos/química , Estudos de Casos e Controles , Doença Crônica , Mucosa Gástrica/patologia , Gastrite/genética , Gastrite/patologia , Gastroscopia , Expressão Gênica , Humanos , Imuno-Histoquímica , Pacientes Ambulatoriais , Índice de Gravidade de Doença , Superóxido Dismutase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...